The androgen receptor (AR) is a hormone-dependent transcription factor that plays important roles in male sexual differentiation and development. Transcription activation by steroid hormone receptors, such as the androgen receptor, is mediated through interaction with co-factors. We recently identified a novel AR-interacting protein, provisionally termed PAK6, that shares a high degree of sequence similarity with p21-activated kinases (PAKs). PAK6 is a 75 kDa protein that contains a 
INTRODUCTION
reactions were carried out at room temperature for 30 min and terminated by addition of SDS-PAGE loading buffer. Samples were analyzed by SDS-PAGE and autoradiography.
Cell Cultures and Transient Transfections:
A monkey kidney cell line (CV-1) containing no detectable levels of endogenous steroid hormone receptor activity was maintained in DMEM medium supplemented with 5% fetal calf serum (HyClone, Denver, CO). Transient transfections were carried out using a LipofectAMINE transfection kit (GIBCO/BRL, Gaithersburg, MD). Approximately 1.5-2x10 4 cells were plated in a 48-well plate 16 hr before transfection. About 200 ng of total plasmid DNA per well were used in the transfection. Approximately 16 hr after transfection, the cells were washed and fed medium containing 5% charcoal-stripped (steroid hormone free) fetal calf serum (HyClone, Denver, CO) in the presence or absence of steroid hormones. Cells were incubated for another 24 hr and luciferase activity was measured as relative light units (RLU) as we described previously (17,39). The RLU from individual transfections were normalized by β-galactosidase activity in the same samples. Individual transfection experiments were done in triplicate and the results are reported as mean RLU/β-galactosidase (+SD) from representative experiments.
RESULTS

Isolation of androgen receptor interacting proteins. To identify AR interacting proteins, we
screened a human prostate library with a bait containing full length AR-LBD. Yeast transformants were selected for growth in medium containing 100 nM R1881. Of 8x10 6 transformants, 155 grew under selective conditions and showed an increased β-gal production in a hormone dependent manner.
Rescue of the plasmids and sequencing of the inserts revealed several different cDNAs. Among them, 56 clones encoded a previously identified AR associated protein, ARA70 (15) , and 43 clones encoded gelsolin, a presumptive calcium-regulated actin filament-capping protein (40) . Two cDNAs (clone numbers P18 and P56) encoded a novel sequence and analysis of these clones with the NCBI GenBank sequence database revealed homology with the C-terminal kinase domains of p21-activated kinases (PAK). We named the novel protein PAK6. To confirm the interaction, we co-transformed by guest on September 1, 2017 http://www.jbc.org/ Downloaded from the P18 clone with various constructs containing either GAL4DBD alone, or the AR fusion proteins with LBD and a partial transactivation domain (pTAD) (Fig 1) . pACT2-PAK6 showed a specific interaction with GAL4DBD-AR-LBD by producing adenine in the presence of androgen, similar to the pACT2-ARA70 positive control (Fig.1A) . A liquid β-gal assay was performed to quantify the interactions. The pACT2-PAK6 showed an approximately 170-fold induction with the pGBT9-AR-LBD in the presence of DHT (Fig.1B) . Our results demonstrate that the LBD of AR specifically interacts with PAK6 in a ligand dependent manner in yeast.
PAK6 is a novel member of the PAK protein family. Sequence analysis revealed that the PAK6 clones isolated from the yeast two-hybrid screen were truncated proteins. To isolate the aminoterminal fragment of PAK6, we performed 5'-RACE. Three positive clones covering different lengths of 5' region were isolated, and the longest was used to generate a full-length clone by fusion with the DNA fragment containing the carboxy-terminal region obtained from the original yeast screening ( Fig.2A) . Sequence analysis of the full length clone revealed a methionine initiation codon at nucleotide 198, followed by an open reading frame encoding a 681-amino acid protein with a predicted molecular mass of 75 kDa (Accession number: AF276893). Using in vitro transcription and translation, a 75kDa protein was generated by several different PAK6 plasmids ( Figure 2B ), confirming the identity of the predicted initiation codon.
The PAK family of proteins share a highly conserved amino-terminal CRIB domain (underlined in Fig. 2C ) and a carboxy-terminal protein kinase domain (boxed in Fig. 2C) . A high degree of sequence similarity was observed when PAK6 was aligned with these two regions of other human PAKs. PAK6 shares 8 consensus residues in the CRIB domain with other PAK proteins (Fig. 2D) .
The protein kinase domain of PAK spans 300 amino acids and is highly conserved among the family members. Comparison of PAK6 with human PAK1-5 proteins showed that the kinase domain of PAK6 has more than a 50% sequence similarity with PAK1-5, with PAK6 having the highest similarity in this region to PAK4 (78%) and PAK5 (78%). 
PAK6 interacts with AR in vitro & in vivo.
To confirm that the interaction observed in the yeast two-hybrid system is biologically relevant, GST pull-down experiments were carried out with a series of GST-AR fusion proteins (Fig. 3A) (38) . The binding of 35 S-methionine labeled full-length PAK6 protein to GST-AR fusion proteins was analyzed by SDS-PAGE and detected by autoradiography. As seen in Figure 3B , a specific retention of PAK6 protein was observed for the samples with GST-AR LBD. A stronger interaction was detected using two small fragments of LBD consisting of partial LBD and AF2 truncated mutants, pLBD and AF2, suggesting that parts of each domain are dispensable for binding to PAK6. The binding between the LBD of AR and PAK6 was not significantly enhanced by androgen in our GST pull-down experiments. Similar results have been reported for other nuclear receptor co-factors, perhaps due to improper protein folding of the GST fusions (9, 11, 16, 17) . Our results from the GST pull-down experiments further support those of the yeast-two hybrid experiments and suggest that the LBD of AR is required for interaction with PAK6.
To determine whether an interaction between PAK6 and AR occurs in vivo, we tagged PAK6 at its amino terminus with a Flag epitope and expressed tagged PAK6 protein together with AR protein in CV1 cells, which contain low levels of endogenous steroid hormone receptor activity. Both AR and Flag-PAK6 proteins were detected in the transfected cells (Fig 4A) . Whole cell lysates containing equal amounts of AR proteins were immunoprecipitated with normal mouse IgG or an anti-FLAG monoclonal antibody. As shown in Figure 4B , Flag-PAK6 proteins were detected in the anti-Flag immunoprecipitates from cells co-transfected with AR and Flag-PAK6 in the presence or absence of DHT (Lanes 1 and 3). With the specific AR antibody, AR protein was only detected in immunoprecipitates from cells co-transfected with AR and Flag-PAK6 in the presence of DHT (Fig.   4C ). These data demonstrated that the interaction between AR and PAK6 occurs in mammalian cells in a ligand-dependent manner.
We further examined interactions between the full length AR and PAK6 in vivo ( and a luciferase reporter driven by the MMTV promoter (MMTVpA3-Luc) were cotransfected with the expression vector in which the partial PAK6 clone isolated originally from the yeast two-hybrid screen was fused to the VP16 activation domain (Fig. 5A ). These constructs were tested for their ability to interact with the AR protein and to activate transcription of the MMTVpA3-luc construct.
Transfection of the PAK6-VP16AD showed a strong induction of luciferase activity, higher than that of VP16 alone or of a random yeast clone (ZF18) isolated from this screening as a negative control (Fig. 5B) . Taken together, the results indicate that the carboxy terminal domain of PAK6 interacts with AR in a natural AR-ARE transcriptional complex on the promoter.
PAK6 is selectively expressed in human testis and prostate. Northern blot analysis was carried out to detect the expression of PAK6 in human tissues using a probe covering 1 to 349 amino acid residues of the PAK6 protein. An approximately 4.5 Kb transcript of PAK6 was detected most abundantly in testis and at lower levels in prostate (Fig. 6A ). There was little or no detectable signal in ovary, intestine, spleen, thymus, peripheral blood leukocytes, and colon. In this study, we also proteins were immunoprecipitated from whole cell lysates using the flag antibody. As shown in Figure 7 , the truncated construct containing the kinase domain exhibited a strong kinase activity with MBP, while the full length PAK6 showed a lower level of activity. These results suggest that PAK6 contains an active kinase domain but its activity is regulated by other regions of the protein, perhaps by the binding of other proteins to the N-terminal CRIB motif.
PAK6 translocates into the nucleus with AR in response to androgen induction. In order to mediate transcription, AR has to translocate into the nucleus in response to induction by androgen. To assess the biological function of PAK6 as an AR interacting protein, it is important to determine what happens to the AR-PAK6 complex upon androgen induction. First, we examined the subcellular localization of PAK6 protein by immunofluorescence. As shown in Figure 8A , the full length PAK6 is mainly localized in the cytoplasm. Treatment with DHT, as previously reported, resulted in a clear induction of AR nuclear translocation but had no effect on the localization of PAK6 when the PAK6 vector alone was expressed in cells ( Fig. 8A ). When AR and PAK6 were cotransfected into cells, they were localized in the cytoplasm in the absence of DHT (Fig. 8B ).
However, with DHT treatment, the full length PAK6 protein was totally translocated into the nucleus and co-localized with AR. These results provide additional data demonstrating that PAK6 specifically interacts with AR in a ligand-dependent manner and, through this interaction, translocates into the nucleus as part of an AR complex. 
DISCUSSION
In this study, we identified a new p21-activated kinase, PAK6, and demonstrated a specific interaction between PAK6 and AR. These findings link PAK-mediated signaling to the steroid hormone receptor pathway, suggesting a novel function for this new PAK member. Many AR interacting proteins have been identified thus far and in general they are transcription factors that play direct roles in regulating transcription. The identification of PAK6, a protein kinase, as an AR interacting protein is therefore quite interesting and novel. Consequently, we have spent a considerable amount of effort to prove that the interaction between PAK6 and AR is a truly physiological protein-protein interaction. We showed that the LBD of AR is necessary and sufficient for the interaction with PAK6 in an androgen-dependent manner in the yeast two-hybrid system, suggesting that conformational changes in the LBD of AR upon binding to ligand are necessary for PAK6 to bind to AR protein. The interaction was further confirmed in vivo in mammalian cells. In the co-immunprecipitation experiments, the AR protein specifically interacted with Flag-tagged PAK6.
The interaction between AR and PAK6 proteins was also observed in the mammalian one-hybrid experiment, in which PAK6 interacted with AR in the active AR-ARE transcription complex. In both cases, androgen was absolutely required for the interaction. Finally, we demonstrated a dynamic interaction between AR and PAK6 in the immunofluorescence studies. As shown in Figure 7 , PAK6 co-translocates into nuclei with AR in response to androgen induction. Taken together, the data clearly indicate that the interaction between AR and PAK6 is biologically significant.
To search for the biological consequences of the interaction between PAK6 and AR, we tested whether PAK6 was able to directly alter AR-mediated transcription. In transient transfection experiments, we showed that PAK6 inhibited ligand-dependent, AR-mediated transactivation.
Importantly, PAK6 was shown to have no effect on another steroid hormone receptor, the by guest on September 1, 2017 http://www.jbc.org/ Downloaded from glucocorticoid receptor (GR), under identical experimental conditions (Fig.9 ). These data suggest that the specific repression of AR by PAK6 may be one of the biological consequences of their proteinprotein interaction. In the future it will be interesting to determine whether PAK6 interacts with other nuclear receptors.
Although both physical and functional interaction between PAK6 and AR has been demonstrated, the mechanism by which PAK6 represses AR function is unknown. Given the fact that Recent studies have shown that the CRIB domain of PAK1 interacts intramolecularly with its catalytic domain to inhibit the kinase activity by forming a closed and inactive configuration (52). We have shown that the full length PAK6 has much less kinase activity than the carboxy-terminal kinase by guest on September 1, 2017 http://www.jbc.org/ Downloaded from domain, suggesting that a similar auto-inhibition mechanism for kinase activity may also exist in PAK6. Thus far, all known PAKs are found localized mainly in the cytoplasm. PAK4 was shown to translocate from the perinuclear cytoplasm to Golgi membranes with activated CDC42 (27). Our finding that PAK6 co-translocates into the nucleus with AR suggests that PAK6 may have a novel function unlike other PAKs. It will be interesting to determine whether AR affects PAK6 functions through their interaction. Further characterization of PAK6 interaction with AR should clarify these issues.
In conclusion, this study demonstrates for the first time that a novel PAK protein, PAK6, specifically interacts with AR. Most importantly, the data indicate a mechanism whereby AR pathways can cross-talk with signaling pathways of the Rho-related small GTPase family. Further studies of the regulation of AR-mediated transcription by PAK6 may provide new insight into the biology of normal prostate and prostate cancer. 
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